Drug Development
DURECT Corporation announces positive Phase I study results with new pain product in development
Published in Medical Letter on the CDC and FDA, January 14th, 2007
We believe that the persistent pain market remains underserved and that DUR-843 has the potential to provide several advantages over existing pain medications.
"We are pleased to add another product candidate to our pipeline and with the rapid progress and positive results thus far," stated James E. Brown, DVM, president and CEO of DURECT. "As a result of our recent collaboration with Nycomed covering POSIDUR, we are in a stronger financial position and therefore have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cancer Vaccines
Data from University of Pittsburgh, Pittsburgh Cancer Institute advance knowledge in cancer vaccines - Alzheimer Disease
Memory Pharmaceuticals reports U.S. FDA release of clinical hold on Alzheimer drug MEM 3454 - Anemia
Data show efficacy of extended dosing of Aranesp in treatment of chemotherapy-induced anemia - Anemia
Phase II data show promise of Aranesp treatment for anemia of cancer - Business & Finance
Adolor discontinues sales force and reports other selected work force reductions - Business & Finance
Migenix updates celgosivir hepatitis C study data, reports Q2 2007 $3.7 million loss - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
